Neximmuneincis A Clinical Stage Biotechnology Company Based In Baltimoremarylandfounded In 2011It Specializes In Antigen Directed Immunotherapies Through Its Proprietary Artificial Immune Modulationaima Cnanotechnology Platformthe Company Develops T Cell Mediated Therapies Aimed At Treating Cancerinfectious Diseasesand Autoimmune Disorders By Mimicking Natural Immune Responses The Aim Platform Employs Nanoparticles That Act As Synthetic Dendritic Cellsdelivering Targeted Immune Modulating Signals To T Cellsthis Technology Allows For The Activation Of T Cells Against Cancer And Infections Or Their Suppression In Autoimmune Conditionsneximmune S Clinical Pipeline Includes Candidates Like Nexi 001 For Acute Myeloid Leukemianexi 002 For Multiple Myeloma And Solid Tumorsand Nexi 003 For Hpv Related Cancersthe Company Focuses On Therapies With Curative Potentialemphasizing Anti Tumor Potency And T Cell Persistence
